


RECEIVED

APR 10 2002

TECH CENTER 1600/2900

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. (Optional) VPHAR1460- 2	Serial No.: 09/446, 783
	Applicant(s): Desai, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: May 16, 2000	Group Art Unit: 1616



U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
RMD	AA 2,660,556	11/24/53	Butler, D G	204	171	09/08/52
	AB 4,073,943	02/14/78	Wretlind et al	424	358	03/12/76
	AC 4,671,954	06/09/87	Goldberg et al	424	450	02/04/86
	AD 5,059,699	10/22/91	Kingston et al	549	511	08/28/90
	AE 5,145,684	09/08/92	Liversidge et al	424	489	01/25/91
RMD	AF 5,641,803	06/24/97	Canetta et al	514	449	10/18/95

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
RMD	AG WO 85/00011	03/01/85	PCT	A61K 9	22	No
RMD	AH WO 94/10980	26/05/94	PCT	A61K 9	14	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

RMD	AI	Bazile, et al., "Body distribution of fully biodegradable [¹⁴ C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats" <i>Biomaterials</i> 13 (15):1093-1102 (1992)
RMD	AJ	Boury, et al., "Dilatational Properties of Adsorbed Poly(D,L-lactide) and Bovine Serum Albumin Monolayers at the Dichloromethane/Water Interface" <i>Langmuir</i> 11:1636-1644 (1995)

EXAMINER 	DATE CONSIDERED 4/19/02
--------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. (Optional) VPHAR1460-1	Serial No.: 09,25,96,783
	Applicant(s): Desai, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: May 16, 2000	Group Art Unit: 1616




RECEIVED
 APR 10 2002
 TECH CENTER 1600/2900

<i>RMD</i>	AK	Brown, et al., "A Phase I Trial of Taxol Given by a 6-Hour Intravenous Infusion" <i>Journal of Clinical Oncology</i> 9 (7):1261-1267 (1991)
	AL	Calvo, et al., "Comparative <i>in Vitro</i> Evaluation of Several Colloidal Systems, Nanoparticles, Nanocapsules, and Nanoemulsions, as Ocular Drug Carriers" <i>Journal of Pharmaceutical Sciences</i> 85 (5):530-536 (1996)
	AM	Cavalier, et al., "The formation and characterization of hydrocortisone-loaded poly((±)-lactide) microspheres" <i>J. Pharm. Pharmacol.</i> 38:249-253 (1986)
	AN	Donehower, et al., "Phase I Trial of Taxol in Patients With Advanced Cancer" <i>Cancer Treatment Reports</i> 71 (12):1171-1177 (1987)
	AO	Einzig, A. I., "Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma" <i>Cancer Investigation</i> 9 (2):133-136 (1991)
	AP	Friberg, S. E., "MICROEMULSIONS" <i>J. Dispersion Science and Technology</i> 6 (3):317-337 (1985)
	AQ	Grem, et al., "Phase I Study of Taxol Administered as a Short Iv Infusion Daily for 5 Days" <i>Cancer Treatment Reports</i> 71 (12):1179-1184 (1987)
	AR	Holmes, et al., "PHASE II STUDY OF TAXOL IN PATIENTS (PT) WITH METASTATIC BREAST CANCER (MBC)" <i>Proceedings of Asco</i> 10 (113):60 (1991)
	AS	Holmes, et al., Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer" <i>Journal of the National Cancer Institute</i> 83 (24):1797-1805 (1991)
	AT	Koeller, et al., "A PHASE I/PHARMACOKINETIC STUDY OF TAXOL GIVEN BY A PROLONGED INFUSION WITHOUT PREMEDICATION" <i>Proceedings of Asco</i> 8 (319):82 (1989)
	AU	Kris, et al., "Phase I Trial of Taxol Given as a 3-Hour Infusion Every 21 Days" <i>Cancer Treatment Reports</i> 70 (5):605-607 (1986)
<i>RMD</i>	AV	Kumar, et al., "BINDING OF TAXOL TO HUMAN PLASMA, ALBUMIN AND α ₁ -ACID GLYCOPROTEIN" <i>Research Communications in Chemical Pathology and Pharmacology</i> 80 (3):337-344 (1993)

EXAMINER <i>R. D. [Signature]</i>	DATE CONSIDERED 4/19/02
--------------------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. (Optional) VPHAR1460-1	Serial No.: 09/446,783
	Applicant(s): Desai, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: May 16, 2000	Group Art Unit: 1616




RECEIVED
 APR 10 2002
 TECH CENTER 1600/2800

<i>Romy</i>	AW	Lee, T. K., "Serum Albumin Beads: An Injectable, Biodegradable System for the Sustained Release of Drugs" <i>Science</i> 213:233-235 (1981)
	AX	Leucuta, et al., "Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects" <i>International Journal of Pharmaceutics</i> 41:213-217 (1988)
	AY	Lorenz, et al., "Histamine Release in Dogs by Cremophor El and its Derivatives: Oxethylated Oleic Acid is the Most Effective Constituent" <i>Agents and Actions</i> 7 (1) 63-67 (1977)
	AZ	Mathew, et al., "Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity" <i>J. Med. Chem.</i> 35:145-151 (1992)
	BA	Merisko-Liversidge, "Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs" <i>Pharmaceutical Research</i> 13:2 272-278 (1996)
	BB	Miller, et al., "Reporting Results of Cancer Treatment" <i>Cancer</i> 47:207-214 (1981)
	BC	Reichman, et al., "Paclitaxel and Recombinant Human Granulocyte Colony-Stimulating Factor as Initial Chemotherapy for Metastatic Breast Cancer" <i>Journal of Clinical Oncology</i> 11:10 1943-1951 (1993)
	BD	Rosoff, M., "The Nature Microemulsions" <i>Progress in Surface and Membrane Science</i> 12:405-477 (1978)
	BE	Rowinsky, et al., "Phase I and Pharmacodynamic Study of Taxol in Refractory Acute Leukemias" <i>Cancer Research</i> 49:4640-4647 (1989)
	BF	Stemmer, et al., "High-Dose Paclitaxel, Cyclophosphamide, and Cisplatin With Autologous Hematopoietic Progenitor-Cell Support: A Phase I Trial" <i>Journal of Clinical Oncology</i> 14 (5):1463-1472 (1996)
<i>Romy</i>	BG	Wani, et al., "Plant Antitumor Agents; VI: The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from <i>Taxus brevifolia</i> " <i>Journal of the American Chemical Society</i> 93 (9):2325-2327 (1971)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>4/18/02</i>
-----------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. (Optional) VPHAR1460-1	Serial No.: 09/446,783
	Applicant(s): Desai, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: May 16, 2000	Group Art Unit: 1616



RECEIVED
 APR 10 2002
 TECH CENTER 1600/2000

<i>Rmt</i>	BH	Weiss, et al., "Hypersensitivity Reactions From Taxol" <i>Journal of Clinical Oncology</i> 8 (7):1263-1268 (1990)
<i>Rmt</i>	BI	Wiernik, et al., "Phase I Clinical and Pharmacokinetic Study of Taxol" <i>Cancer Research</i> 47:2486-2493 (1987)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 4/19/02
--------------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.